ArticleJournal of eating disorders2026
Effectiveness without safety: a response to Duggan, Hardy, and Waller (2026).
Article in Journal of eating disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This commentary responds to Duggan, Hardy, and Waller's systematic review and meta-analysis of cognitive-behavioural therapy (CBT) for outpatients with anorexia nervosa (AN). Although the review synthesises evidence of clinical benefit, it does not define, extract, or discuss iatrogenic harm or reasons for dropout. This omission limits what can be inferred from the review's conclusions. Effectiveness and safety are distinct evidentiary domains: improvement in weight or eating disorder (ED) symptoms does not demonstrate absence of iatrogenic harm, especially when clinical trials have not systematically defined, monitored, or reported treatment-related risks. Evidence-based care requires not only evidence of effectiveness, but also evidence about safety. This commentary argues that evidence syntheses may produce an unduly favourable account of treatment impact when they quantify and emphasise benefit without equivalent attention to iatrogenesis, weakening informed consent and obscuring patient-reported experiences that may not be captured by symptom or weight outcomes alone. The paper considers methodological, clinical, ethical, epistemic, and intersectional implications of this asymmetry. It recommends that future ED clinical trials and systematic reviews evaluate benefit and harm together, undertake balanced assessments of benefits versus risks, use clearer harm definitions and patient-reported measures, report reasons for dropout, assess longer-term outcomes, and involve lived experience contributors substantively in study design, interpretation, and translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.